INTRODUCTION
Depression is a major public health problem with high prevalence rates worldwide and an increased risk of comorbidity and mortality, especially in the elderly. Family studies provide evidence that there is a genetic component to depressive disorders, although only a small number of candidate genes have been identified . Several lines of evidence suggest a role for estrogen in depression. Depression results [1 ] from a disruption in the normal brain neurochemistry, including depletion in the levels of serotonin, and estrogen has been shown to modulate neurotransmitter turnover and enhance serotonergic activity . Numerous epidemiological studies support these observations, [2 ] linking estrogen with depressed mood and antidepressant response (see for review ). Estrogen-containing hormone treatment (HT) is [3 ] also effective in improving the depressed mood of perimenopausal women , although its use in older postmenopausal women remains [4 ] more controversial. However given that the actions of estrogen occur in large part through intracellular activation of the estrogen receptors (ER-and ER-), it is surprising that very few studies have examined whether ER polymorphisms can modify the risk of depression.
α β
Polymorphisms of these receptors have been associated previously, although not consistently, with estradiol levels , vasomotor [5 ] symptoms , and other brain disorders like Alzheimer s disease , . Genetic variation in the ER may also influence a person s
[6 ] '
susceptibility to developing depression and may modify estrogen signalling and thus the effect of HT on mood, but this has not been examined previously. This current study aimed to investigate the association between severe late-life depression and five ER-and ER-α β polymorphisms. Given the lack of data in this field, we did not hypothesize which genotypes would be most frequent in depressed participants. Analysis will be stratified by gender so that individual associations in men and women can be identified, and the potential modifying effect of HT use in women can be evaluated.
METHODS AND MATERIALS

Study Population
This analysis uses data collected at baseline from the Three City Study (3C), an ongoing multi-centre longitudinal study involving the French cities Bordeaux, Dijon and Montpellier . Recruitment of the cohort took place between 1999 and 2001 with eligible participants [9 ] (aged over 65 years and non-institutionalised) being randomly selected from the electoral rolls in the three cities. Thirty-seven percent of contacted people agreed to participate and were administered interviews by trained staff and underwent a number of clinical examinations.
The study protocol was approved by the Ethical Committee of the University Hospital of Kremlin-Bic tre (France) and participants ê provided written informed consent. Of the 9097 dementia-free participants initially recruited in the 3C study, those who were not assessed for current and past psychiatric symptomatology (n 953), or who did not provide blood samples for genotyping analysis (n 1291) could = = not be included in this analysis. We also excluded participants with incomplete genotyping data (n 237) or missing data concerning the = key covariates (n 599), such that all of the analyses presented are based on the same population sample. Participants excluded from this = analysis were significantly more likely to have current depression ( 73.9, p<0.0001), and were more likely to be female ( 38.7,
p<0.001), however there was no significant difference in terms of the distribution of ER polymorphism genotypes.
Depression Measures
The Mini-International Neuropsychiatry Interview (MINI), a standardized psychiatric examination which has been validated in the general population , was used for the diagnosis of current and past major depressive disorder (MDD), according to the Diagnostic and [10 ] Statistical Manual of Mental Disorders (DSM-IV) criteria. Severity of depressive symptoms was assessed with the Centre for
Epidemiology Studies Depression Scale (CES-D)
. Participants with a DSM-IV diagnosis of current MDD or those scoring above the [11 ] clinical cut-off for probable cases of depression (CES-D 23) ,were classified as having current severe depression in this analysis.
Current use of antidepressants, validated by presentation of the prescription or the medication itself, was also considered as a covariate in the analysis.
Estrogen Receptor Polymorphisms
Fasting venous blood samples were taken from the participants at baseline. Blood was collected on EDTA and DNA was extracted from white blood cells (Puregene kit, Qiagen, France) and stored at 80 C. Genotyping was performed by Kbiosciences (Hoddesdon −°H erts, UK) using their competitive allele-specific PCR Single-Nucleotide Polymorphism (SNP) genotyping system (KASPar). The amplified PCR products were analysed by fluorescence scanning in a BMG labtech Pherastar scanner and the results were interpreted with their KlusterCaller 1.1 software. The error rate for the KASPar assay system is less than 0.3 . limitations. Cognitive impairment was defined as having a Mini-Mental State Examination (MMSE) score less than 26 and questionnaires concerning sleeping habits were used to define insomnia . Current use of HT at the time of the baseline interview was validated by [22 ] presentation of the prescription or the medication itself.
Information on the participant s health was obtained through detailed medical questionnaires, a complete inventory of all drugs used ' within the preceding month and from fasting blood samples. These questionnaires included their history of vascular diseases (angina pectoris, myocardial infarction, stroke, cardiovascular surgery, bradycardia or palpitations), other chronic illnesses (asthma, diabetes [ fasting glucose 7.0 mmol/l or reported treatment , hypercholesterolemia total cholesterol 6.2 mmol/l , hypertension resting blood
pressure 160/95 mm Hg or treated and thyroid problems) or cancer diagnosis within the last two years. Participants were classified as
having comorbidity if they suffered from vascular disease, more than 1 chronic illness or a recent cancer.
Statistical Analysis
A test was used to compare the observed allele frequencies with those expected under the Hardy Weinberg equilibrium. The
association between baseline socio-demographic and clinical variables with both depression and ER polymorphisms was examined using t -tests, ANOVA and chi-squared tests. Due to the statistically significant interactions between gender and depression, all subsequent analyses were undertaken separately for males and females. Genotype frequencies of the ER polymorphisms were compared between depressed and non-depressed participants using logistic regression models. Adjustment was made for covariates that were significantly associated with depression in this sample and which remained significant in the final multivariate models. The potential interaction between ER polymorphisms and the use of estrogen-containing HT in women was also considered, based on our hypothesis that a priori ER polymorphisms could mediate the effect of estrogen on depression. There was no indication of collinearity between the covariates in the adjusted models. SAS version 9.1 (SAS Institute, Inc., Cary, North Carolina, USA) was used for all of the analyses and all tests were two-tailed, with a significance level of p<0.05.
RESULTS
Participant s characteristics '
Baseline characteristics of the 6017 participants are summarized in . They ranged in age from 65 to 96 years with a mean of 73 Table 1 years. Men and women differed significantly on all socio-demographic and health variables examined, with the exception of age. Women were significantly more likely to use antidepressants, to have current depressive symptoms and to have a current or past diagnosis of MDD (
). Overall 564 participants were diagnosed with current severe depression (CES-D 23 or current MDD), with a higher prevalence Table 1 ≥ rate in women compared to men (12.9 vs. 4.4 respectively, 123, p<0.001).
Polymorphism frequencies according to depression status
The overall distribution of genotypes in both sexes was not significantly different from those predicted by the Hardy-Weinberg equilibrium, except in the case of the ER-rs1271572 polymorphisms in women ( 5.7, p 0.02). The ER-polymorphisms are known
to be in strong linkage disequilibrium with one another , as are the three ER-polymorphisms examined . Genotype frequencies for [16 ] β [15 ] each of the ERs according to the participant s depression status are given in . There was no significant difference in the genotype ' Table 2 distribution between men and women, although women were more likely to be heterozygous for ER-rs4986938 (49.6 of women overall β % had the GA genotype compared with 46.6 of men, 5.7, p 0.06). For both sexes, the frequency of the AA genotype for ER-
rs1256049 was very small so these participants were grouped with those heterozygous GA for subsequent analysis.
ER polymorphisms and depression
The results of the multivariate logistic regression analyses for the associations between ER polymorphisms and depression are shown in . In men the only borderline significant association was a 1.7 times increase in current severe depression with the AA versus the Table 3 GG genotype of ER-rs4986938. None of the other polymorphisms showed any significant association with depression in men. 
ER x HT interaction
When the potential modifying effect of HT use on the association between these ER polymorphisms and severe depression in women was examined, there was a non-significant trend for an interaction between ER-rs1256049 and current HT (interaction term, p 0.08 in β = the multivariate adjusted model shown on ). Subsequent analysis stratified by current HT use revealed that women who were not Table 3 using treatment (n 2986) were significantly more likely to have current severe depression with the GA/AA genotype (OR: 1.72, 95 CI: = % 1.17 2.50, p 0.005). In stark contrast, among women who were using HT (n 539), the GA/AA genotype was not associated with the risk In study of 106 Korean women . The only previous study to examine the association between ER polymorphisms and MDD (based on [25 ] the Hamilton Scale and DSM-IV criteria) reported that the frequency of the rs2234693 CC genotype was significantly higher in 126 midlife Chinese women (mean age 46.7) than in the 89 controls . In our larger study of 3525 elderly women however, the CC and GG [26 ] genotypes of the rs2234693 and rs9340799 polymorphisms respectively were associated with a significant decrease in current severe depression (defined as a current MDD based on DSM-IV criteria or severe depressive symptoms using a CES-D score of 23 or greater). In post-hoc analysis we did not find a significant association with these ER-polymorphisms and moderate depressive symptoms alone α (CES-D 16, supplementary data). Our findings thus relate specifically to a severe clinical level of current depression.
≥
Potential interaction between ER-polymorphism and HT β
The association between the ER-and depression has been insufficiently studied. There is one report of a non significant association Korean study of 43 women with post-menopausal depression and 63 controls, no significant association was found with rs1256049 or rs4986938 . Here we find that the ER-rs1256049 polymorphism was significantly associated with an increased likelihood of severe [25 ] β depression in women, but only for those non-HT users. No significant association was observed for women who were currently using HT.
It has been shown previously that ER polymorphisms and HT can interact to influence health outcomes in women , . To our [14 16 ] knowledge however, no study has examined whether such an interaction can modify the risk of depression, despite several RCTs demonstrating the psycho-protective effects of HT . Our finding provides some preliminary evidence that HT could be beneficial for [4 ] certain genetically vulnerable women, by reducing the risk of depression associated with the ER-rs1256049 polymorphism. 
ER polymorphisms and depression in men
We found no significant association between ER-polymorphisms and moderate or severe depression in men ( and α   Table 3 Supplementary Table) , in accordance with the two previous studies that have been conducted , . The rs2234693 and rs9340799 [24 26 ] polymorphisms were not associated with MDD in a small case-control study of middle-aged Chinese men , nor in the Rotterdam study [26 ] of depressive symptoms . Neither of these studies however, examined associations with ER-. We report here that the AA allele of the [24 ] β ER-rs4986938 may increase the likelihood of depression specifically in men, although this was of borderline significance. In a similar β manner, one of the few prior studies examining this polymorphism reported a higher frequency of the A allele in men with Alzheimer s ' disease, but no such association in women .
[27 ] and Alzheimer s disease , although not consistently. These polymorphisms have also shown [13 ] ' [7 ] significant associations with estradiol levels in postmenopausal women (lower estradiol with the T (rs2234693) and A (rs9340799) alleles)[
Biological hypothesis linking ER and depression
ER-and ER-classically function as ligand-activated transcription factors and can affect hundreds of genes, including regulation of
, and in a similar manner with bone density and fractures (higher bone mass density and lower fractures for the rs9340799 genotype 19 ]
GG) (see for meta-analysis
). This would support earlier findings that estrogen may have a protective effect against depression .
[17 ] [29 ] Our data suggest distinct genetic vulnerability to depression for men and women. Different polymorphisms of the ER-increased the β likelihood of severe depression in men and women, while in women only the ER-polymorphisms were associated with late-life α depression. There are numerous mechanisms which could help explain these sex differences (see for review ). Although male and [30 ] females have a similar distribution of ER-and in the brain, there appears to be differences in the level of expression of these receptors α β in various regions. Our results may partly account for gender differences in depression prevalence and highlight the need for a sex-specific approach to the development of novel hormone-based therapies.
Study limitations and strengths
Limitations to this study include the relatively low response rate, which limits the ability to generalise these findings as study volunteers tend to be better educated and healthier than the overall population. Participants diagnosed with probable/possible dementia at inclusion (n 217) were excluded from this analysis to minimise recall bias, however as such participants may have higher rates of = depressive symptoms, this could have decreased the overall power of the study and possibly underestimating the associations found.
Possible prescription bias in relation to women who are given HT should also be taken into account, although we have controlled for numerous potential confounding factors in the analysis. The results of this analysis were not adjusted for multi-comparisons, as there was a strong biological rationale for investigating these five specific associations, given the extensive scientific literature supporting a a priori role for estrogen in depression. The usefulness of a Bonferroni correction in this study is thus questionable and would result in an [31 ] inflated type 2 error rate, especially given that the correction assumes independence of the tests, but both ER-polymorphisms are in α strong linkage disequilibrium , as are the three ER-polymorphisms . It remains likely however, that based on the 5 significance
level, one of the significant associations found occurred merely by chance. Finally, it should be noted that in this study we report associations between ER polymorphisms and the prevalence of late-life depression, but have not differentiated the independent associations with depression incidence and disease duration.
This study is strengthened by its sample size and population-based design, as well as the inclusion of both men and women to enable the assessment of independent sex-specific associations. Depression was assessed by trained staff using two distinct measures, including a structured diagnostic interview, which have been validated in the general population . Severity ratings allowed us to examine [10 ] separately the relationship between moderate depressive symptoms and severe depression, with ER genotypes. Although our analyses have adjusted for a large range of socio-demographic and health variables, including past depressive episodes, it is still possible that there are unrecognised factors which could help explain our findings. Replication of our findings in other large population-based studies is needed.
We report here that polymorphisms of the ER-in particular are associated with depression in older women. In addition, there was α some evidence that current HT modified the association between ER-rs1256049 and severe depression in women. These findings suggest β the possibility that some women may be genetically more susceptible than others to the psycho-protective effects of HT. This could have important clinical applications, suggesting the potential for offering tailored hormonal therapies based on genetic markers for the treatment of mood disorders in women and perhaps men, via the development of ER selective effectors.
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